Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XCUR17
- Development stage
- Unknown
- Lead developer
- Exicure
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
XCUR17 is an antisense spherical nucleic acid (SNA) drug candidate designed to target the mRNA encoding interleukin 17 receptor alpha (IL-17RA). By inhibiting IL-17RA expression through RNA interference, it aims to reduce inflammation associated with diseases such as psoriasis. Developed by Exicure and Dermelix Biotherapeutics, XCUR17 has demonstrated significant improvements in clinical scores for psoriasis in Phase 1 trials and has shown efficacy in preclinical models by reducing IL-17RA levels and related inflammatory markers. Its development has been suspended for indications including alopecia, Netherton syndrome, and psoriasis[1][2][3][4][5].
02
Targets
IL-17R (Interleukin 17 Receptor)IL17RA (IL-17RA)
Beyond the preview
Go deeper on XCUR17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XCUR17.